Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma.

Jha A, de Luna K, Balili CA, Millo C, Paraiso CA, Ling A, Gonzales MK, Viana B, Alrezk R, Adams KT, Tena I, Chen A, Neuzil J, Raygada M, Kebebew E, Taieb D, O'Dorisio MS, O'Dorisio T, Civelek AC, Stratakis CA, Mercado-Asis L, Pacak K.

Front Oncol. 2019 Feb 22;9:53. doi: 10.3389/fonc.2019.00053. eCollection 2019.

2.

Technical Note: Single time point dose estimate for exponential clearance.

Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS.

Med Phys. 2018 May;45(5):2318-2324. doi: 10.1002/mp.12886. Epub 2018 Apr 16.

3.

90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.

Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS.

J Nucl Med. 2018 Nov;59(11):1692-1698. doi: 10.2967/jnumed.117.202903. Epub 2018 Mar 9.

4.

Safety and accuracy of 68Ga-DOTATOC PET/CT in children and young adults with solid tumors.

Abongwa C, Mott S, Schafer B, McNeely P, Abusin G, O'Dorisio T, Zamba G, O'Dorisio MS, Menda Y.

Am J Nucl Med Mol Imaging. 2017 Nov 1;7(5):228-235. eCollection 2017.

5.

Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Abad C, Jayaram B, Becquet L, Wang Y, O'Dorisio MS, Waschek JA, Tan YV.

J Neuroinflammation. 2017 Aug 4;14(1):157. doi: 10.1186/s12974-017-0927-1. No abstract available.

6.

Localization of Unknown Primary Site with 68Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.

Menda Y, O'Dorisio TM, Howe JR, Schultz M, Dillon JS, Dick D, Watkins GL, Ginader T, Bushnell DL, Sunderland JJ, Zamba GKD, Graham M, O'Dorisio MS.

J Nucl Med. 2017 Jul;58(7):1054-1057. doi: 10.2967/jnumed.116.180984. Epub 2017 Feb 2.

7.

Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.

Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR.

Pancreas. 2017 Feb;46(2):151-156. doi: 10.1097/MPA.0000000000000734.

8.

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage.

Abad C, Jayaram B, Becquet L, Wang Y, O'Dorisio MS, Waschek JA, Tan YV.

J Neuroinflammation. 2016 Jun 29;13(1):169. doi: 10.1186/s12974-016-0626-3. Erratum in: J Neuroinflammation. 2017 Aug 4;14 (1):157.

9.

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.

Bushnell DL, Madsen MT, O'cdorisio T, Menda Y, Muzahir S, Ryan R, O'dorisio MS.

EJNMMI Res. 2014 Dec;4(1):38. doi: 10.1186/s13550-014-0038-2. Epub 2014 Sep 10.

10.

Pancreastatin predicts survival in neuroendocrine tumors.

Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2014 Sep;21(9):2971-80. doi: 10.1245/s10434-014-3728-0. Epub 2014 Apr 22.

11.

Choroidal schwannoma in a 6-month-old girl.

Chen JJ, Kamberos NL, O'Dorisio MS, Syed NA, Boldt C.

J AAPOS. 2014 Apr;18(2):197-9. doi: 10.1016/j.jaapos.2013.11.017.

PMID:
24698624
12.

GIPR expression in gastric and duodenal neuroendocrine tumors.

Sherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR.

J Surg Res. 2014 Aug;190(2):587-93. doi: 10.1016/j.jss.2014.01.044. Epub 2014 Jan 29.

13.

G-protein coupled receptor expression patterns delineate medulloblastoma subgroups.

Whittier KL, Boese EA, Gibson-Corley KN, Kirby PA, Darbro BW, Qian Q, Ingram WJ, Robertson T, Remke M, Taylor MD, O'Dorisio MS.

Acta Neuropathol Commun. 2013 Oct 10;1:66. doi: 10.1186/2051-5960-1-66.

14.

Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.

Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR.

Surgery. 2013 Dec;154(6):1206-13; discussion 1214. doi: 10.1016/j.surg.2013.04.052.

15.

Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.

Carr JC, Sherman SK, Wang D, Dahdaleh FS, Bellizzi AM, O'Dorisio MS, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S739-S746. doi: 10.1245/s10434-013-3318-6. Epub 2013 Oct 10.

16.

Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.

Menda Y, Ponto LL, Schultz MK, Zamba GK, Watkins GL, Bushnell DL, Madsen MT, Sunderland JJ, Graham MM, O'Dorisio TM, O'Dorisio MS.

Pancreas. 2013 Aug;42(6):937-43. doi: 10.1097/MPA.0b013e318287ce21.

17.

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ, Zaknun JJ.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6. Erratum in: Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):584. O'Dorisiol, T M [corrected to O’Dorisio, T M].

18.

Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.

Carr JC, Boese EA, Spanheimer PM, Dahdaleh FS, Martin M, Calva D, Schafer B, Thole DM, Braun T, O'Dorisio TM, O'Dorisio MS, Howe JR.

Surgery. 2012 Dec;152(6):998-1007. doi: 10.1016/j.surg.2012.08.040.

19.

Management of neuroendocrine tumors in children, adolescents, and young adults.

Howell DL, O'Dorisio MS.

J Pediatr Hematol Oncol. 2012 May;34 Suppl 2:S64-8. doi: 10.1097/MPH.0b013e31824e3885. Review.

PMID:
22525409
20.

Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry.

Baumhover NJ, Martin ME, Parameswarappa SG, Kloepping KC, O'Dorisio MS, Pigge FC, Schultz MK.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5757-61. doi: 10.1016/j.bmcl.2011.08.017. Epub 2011 Aug 8.

21.

Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse.

Fabricius D, Karacay B, Shutt D, Leverich W, Schafer B, Takle E, Thedens D, Khanna G, Raikwar S, Yang B, Desmond ME, O'Dorisio MS.

Pancreas. 2011 Aug;40(6):861-71. doi: 10.1097/MPA.0b013e318214c783.

PMID:
21697765
22.

Neuroendocrine tumors in children and young adults: rare or not so rare.

Sarvida ME, O'Dorisio MS.

Endocrinol Metab Clin North Am. 2011 Mar;40(1):65-80, vii. doi: 10.1016/j.ecl.2010.12.007. Review.

PMID:
21349411
23.

Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.

Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF.

Pediatr Blood Cancer. 2011 Jan;56(1):50-7. doi: 10.1002/pbc.22559.

24.

Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors.

Menda Y, O'Dorisio MS, Kao S, Khanna G, Michael S, Connolly M, Babich J, O'Dorisio T, Bushnell D, Madsen M.

J Nucl Med. 2010 Oct;51(10):1524-31. doi: 10.2967/jnumed.110.075226. Epub 2010 Sep 16.

25.

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.

Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS).

Pancreas. 2010 Aug;39(6):775-83. doi: 10.1097/MPA.0b013e3181ebb4f0.

26.

A DOTA-peptide conjugate by copper-free click chemistry.

Martin ME, Parameswarappa SG, O'Dorisio MS, Pigge FC, Schultz MK.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4805-7. doi: 10.1016/j.bmcl.2010.06.111. Epub 2010 Jun 25.

27.

2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells.

Shutt DC, O'Dorisio MS, Aykin-Burns N, Spitz DR.

Cancer Biol Ther. 2010 Jun 1;9(11):853-61. Epub 2010 Jun 26.

28.

90Y-edotreotide for metastatic carcinoid refractory to octreotide.

Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA.

J Clin Oncol. 2010 Apr 1;28(10):1652-9. doi: 10.1200/JCO.2009.22.8585. Epub 2010 Mar 1.

29.

Development of a highly sensitive and specific carboxy-terminal human pancreastatin assay to monitor neuroendocrine tumor behavior.

O'Dorisio TM, Krutzik SR, Woltering EA, Lindholm E, Joseph S, Gandolfi AE, Wang YZ, Boudreaux JP, Vinik AI, Go VL, Howe JR, Halfdanarson T, O'Dorisio MS, Mamikunian G.

Pancreas. 2010 Jul;39(5):611-6. doi: 10.1097/MPA.0b013e3181c68d7a.

PMID:
20124939
30.

Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, Jacobson AF.

J Nucl Med. 2009 Sep;50(9):1448-54. doi: 10.2967/jnumed.108.058701. Epub 2009 Aug 18.

31.

The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.

Nam C, Case AJ, Hostager BS, O'Dorisio MS.

J Mol Neurosci. 2009 Feb;37(2):160-7. doi: 10.1007/s12031-008-9119-x. Epub 2008 Jul 29.

PMID:
18663606
32.

Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.

O'Dorisio MS, Khanna G, Bushnell D.

Cancer Metastasis Rev. 2008 Dec;27(4):665-77. doi: 10.1007/s10555-008-9153-8. Review.

PMID:
18581060
33.

Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors.

Khanna G, Bushnell D, O'Dorisio MS.

Oncologist. 2008 Apr;13(4):382-9. doi: 10.1634/theoncologist.2007-0175. Review.

34.

ECM1 expression in thyroid tumors--a comparison of real-time RT-PCR and IHC.

Lal G, Padmanabha L, Nicholson R, Smith BJ, Zhang L, Howe JR, Robinson RA, O'Dorisio MS.

J Surg Res. 2008 Sep;149(1):62-8. doi: 10.1016/j.jss.2007.10.014. Epub 2007 Nov 26.

PMID:
18374945
35.

Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies.

Khanna G, O'Dorisio MS, Menda Y, Glasier C, Deyoung B, Smith BJ, Graham M, Juweid M.

Pediatr Blood Cancer. 2008 Mar;50(3):561-6.

PMID:
17387742
36.

RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma.

Lal G, Padmanabha L, Smith BJ, Nicholson RM, Howe JR, O'Dorisio MS, Domann FE Jr.

Cancer. 2006 Dec 15;107(12):2752-9.

37.
38.

Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.

Madsen MT, Bushnell DL, Juweid ME, Menda Y, O'Dorisio MS, O'Dorisio T, Besse IM.

J Nucl Med. 2006 Apr;47(4):660-7.

39.
40.

Caspase 8L, a novel inhibitory isoform of caspase 8, is associated with undifferentiated neuroblastoma.

Miller MA, Karacay B, Zhu X, O'Dorisio MS, Sandler AD.

Apoptosis. 2006 Jan;11(1):15-24.

PMID:
16374545
41.

Atypical teratoid/rhabdoid tumor case report: treatment with surgical excision, radiation therapy, and alternative medicines.

Howes TL, Buatti JM, O'Dorisio MS, Kirby PA, Ryken TC.

J Neurooncol. 2005 Mar;72(1):85-8.

PMID:
15803380
42.

Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome.

Hoffman WH, Jueppner HW, Deyoung BR, O'dorisio MS, Given KS.

Am J Med Genet A. 2005 Apr 30;134(3):233-6.

PMID:
15742370
43.

Prognostic value of quantifying apoptosis factor expression in favorable histology wilms tumors.

Miller MA, Karacay B, Breslow NE, Li S, O'Dorisio MS, Grundy PE, Sandler AD.

J Pediatr Hematol Oncol. 2005 Jan;27(1):11-4.

PMID:
15654272
44.

MIBG and somatostatin receptor analogs in children: current concepts on diagnostic and therapeutic use.

Pashankar FD, O'Dorisio MS, Menda Y.

J Nucl Med. 2005 Jan;46 Suppl 1:55S-61S. Review.

45.

Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells.

Sall JW, Klisovic DD, O'Dorisio MS, Katz SE.

Exp Eye Res. 2004 Oct;79(4):465-76.

PMID:
15381031
46.

Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging.

Frühwald MC, Rickert CH, O'Dorisio MS, Madsen M, Warmuth-Metz M, Khanna G, Paulus W, Kühl J, Jürgens H, Schneider P, Müller HL.

Clin Cancer Res. 2004 May 1;10(9):2997-3006.

47.

Two-career families: published data and personal reflections.

O'Dorisio MS, O'Dorisio TM.

Exp Biol Med (Maywood). 2003 Dec;228(11):1266-8. No abstract available.

PMID:
14681541
48.

VIP receptor 1 (VPAC1) promoter targets the expression of a reporter gene to cerebellum and adrenal medulla in transgenic mice.

Karacay B, O'Dorisio MS, Summers M, Robinson M, Bonthius DJ.

Regul Pept. 2003 Nov 15;116(1-3):1-12.

PMID:
14599709
49.

A multi-tyrosinated sst1/2 receptor preferring somatostatin agonist inhibits reflex and immune-mediated secretion in the guinea pig colon.

Cooke HJ, Wang YZ, Wray D, O'Dorisio MS, Woltering EA, Coy DH, Murphy WA, Christofi FL, Gosh P, O'Dorisio TM.

Regul Pept. 2003 Jun 15;114(1):51-60.

PMID:
12763640
50.

A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.

Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.

J Pharmacol Exp Ther. 2003 Aug;306(2):638-45. Epub 2003 May 15.

PMID:
12750439

Supplemental Content

Loading ...
Support Center